Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery

NCT ID: NCT05806346

Last Updated: 2024-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

764 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study is a multi-center randomized prospective placebo-controlled non-inferiority trial.

The study's primary objective is to compare the amounts of postoperative bleeding using two different TXA administration strategies: empirical TXA administration vs. viscoelastic test-based goal-directed TXA administration in cardiovascular surgery.

The secondary objectives include comparing the incidents of hyper-fibrinolysis, thromboembolic complications, and postoperative seizures.

Researchers assumed that goal-directed tranexamic acid (TXA) administration using viscoelastic field tests would not be inferior to the empirical TXA administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. It also would be beneficial in lowering TXA-induced thromboembolic complications and seizures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present study is a multi-center randomized prospective placebo-controlled non-inferiority trial.

This study's primary objective is to compare the amounts of postoperative bleeding during postoperative 24 hours through chest tube drainage using two different tranexamic acid (TXA) administration strategies: empirical TXA administration vs. viscoelastic test-based goal-directed TXA administration in cardiovascular surgery.

The secondary objectives include determining the inter-group differences in hyper-fibrinolysis, thromboembolic complications, and postoperative seizures.

Researchers hypothesized that goal-directed TXA administration using viscoelastic field tests would not be inferior to the empirical TXA administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. Researchers also expect that goal-directed TXA administration would be beneficial in lowering TXA-induced thromboembolic complications and seizure risks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Diseases Vascular Diseases Transfusion Related Complication Coagulation Disorder, Blood Fibrinolysis; Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized prospective double-blind placebo-controlled multicenter non-inferior
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
placebo-controlled

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Empirical 1: TXA and Placebo administration

Tranexamic acid administration, regardless of the result of rotational thromboelastometry.

Placebo administration, at LI60 \< 85 % or A10\< 40 mm in EXTEM of rotational thromboelastometry

Group Type ACTIVE_COMPARATOR

TXA administration

Intervention Type DRUG

Tranexamic acid intravenous administration

Placebo administration

Intervention Type DRUG

Placebo (normal saline) intravenous administration

Empirical 2: TXA administration

Tranexamic acid administration, regardless of the result of rotational thromboelastometry.

Placebo discard, at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry

Group Type ACTIVE_COMPARATOR

TXA administration

Intervention Type DRUG

Tranexamic acid intravenous administration

Goal-directed 1: Placebo administration

Placebo administration, regardless of the result of rotational thromboelastometry.

Tranexamic acid administration at LI60 \< 85 % or A10 \< 40 mm in EXTEM of rotational thromboelastometry

Group Type EXPERIMENTAL

TXA administration

Intervention Type DRUG

Tranexamic acid intravenous administration

Placebo administration

Intervention Type DRUG

Placebo (normal saline) intravenous administration

Goal-directed 2: TXA and Placebo administration

Placebo administration, regardless of the result of rotational thromboelastometry.

Tranexamic acid discard at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry

Group Type EXPERIMENTAL

Placebo administration

Intervention Type DRUG

Placebo (normal saline) intravenous administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TXA administration

Tranexamic acid intravenous administration

Intervention Type DRUG

Placebo administration

Placebo (normal saline) intravenous administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tranexamic acid Placebo (normal saline)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who will undergo elective cardiovascular surgery employing cardiopulmonary bypass
* patients who provide written informed consent

Exclusion Criteria

* pregnancy
* refusal of allogenic blood transfusion
* taking thrombin
* history of thromboembolic and familial hypercoagulability disease
* recent history of myocardial infarction or ischemic cerebral infarction (within 90 days)
* hypersensitive to TXA
* histroy of convulsion or epilepsy
* taking hemodialysis
* history of Heparin-induced thrombocytopenia
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Korea Health Industry Development Institute

OTHER_GOV

Sponsor Role collaborator

Helptrial

UNKNOWN

Sponsor Role collaborator

Asan Medical Center

OTHER

Sponsor Role collaborator

Samsung Medical Center

OTHER

Sponsor Role collaborator

Konkuk University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tae-Yop Kim, MD PhD

Professor of Anesthesiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tae-Yop Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Konkuk University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Konkuk University Medical Center

Seoul, , South Korea

Site Status RECRUITING

Samsung Medical Center

Seoul, , South Korea

Site Status RECRUITING

Asan Medical Center

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tae-Yop Kim, MD PhD

Role: CONTACT

Phone: +82-10-8811-6942

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chung-Sik Oh, MD, PhD

Role: primary

Jung Chan Park, MD

Role: primary

Jaesik Nam

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Nam JS, Oh CS, Kim JY, Choi DK, Oh AR, Park J, Lee JH, Yun SC, Kim KW, Jang MU, Kim TY, Choi IC. A multi-center, double-blind, placebo-controlled, randomized, parallel-group, non-inferiority study to compare the efficacy of goal-directed tranexamic acid administration based on viscoelastic test versus preemptive tranexamic acid administration on postoperative bleeding in cardiovascular surgery (GDT trial). Trials. 2024 Sep 27;25(1):623. doi: 10.1186/s13063-024-08467-1.

Reference Type DERIVED
PMID: 39334224 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HI22C1952-1-3

Identifier Type: -

Identifier Source: org_study_id